Evolent Health, Inc. provided earnings guidance for the fiscal year 2023. For the period, the company expects revenue growth to exceed 25% before any impact from NIA, equating to organic growth of 20%+ and the contribution of seven months of incremental revenue from the IPG acquisition, completed in August.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.89 USD | -1.63% | -1.80% | -30.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.70% | 2.62B | |
+6.26% | 33.06B | |
+20.73% | 7.99B | |
+34.03% | 4.34B | |
-15.76% | 1.46B | |
-25.93% | 1.31B | |
-29.79% | 1.21B | |
+10.99% | 993M | |
-36.79% | 883M | |
-22.03% | 686M |
- Stock Market
- Equities
- EVH Stock
- News Evolent Health, Inc.
- Evolent Health, Inc. Provides Earnings Guidance for the Fiscal Year 2023